FCMR and neoplasm: Upon genetic ablation of Fcmr or blockade of FCMR–ligand interaction with a decoy receptor, this brake on DC activation is released, allowing vigorous uptake of tumor cell-derived antigens and cytokine production that promote T cell activation (Fig. 6f, right).